Companies · Biotechnology

Biotix Holdings Inc.

SAN DIEGO · Biotechnology

Diligence memoA one-page analyst read on Biotix Holdings Inc. — recommendation, valuation, rhythm, risks.
$4.2M
Total raised · real
2
Rounds
1.1×
Latest step-up
Top 61%
Sector rank · raised
Seed
Latest stage · inferred · Fri Apr 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Biotix Holdings Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.13× the median modeled value of Seed Biotechnology companies in 2010–2012 (151 peers) — value vs value, same stage and era.
  • Within the normal band (113% of peer median) for its niche.
Dormant
  • Last raise 14.2 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Biotix Holdings Inc. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
15.3 yr record
Peak capital year was 2012 with $2.2M across 1 filings.
Market position
ahead of 40% of Biotechnology peers
Capital scale is ahead of 40% of Biotechnology peers; modeled value is above 58% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2012: $2.2M across 1 filings.
  • Largest single filing was $2.2M on 2012-04-06.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Biotix Holdings Inc. is one of 4293 Biotechnology companies tracked from SAN DIEGO. By capital raised it ranks mid-pack (ahead of 40% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeed · 2011-03-23 Raised $2.0M (real) Modeled valuation $89M (est)$2.0M$89MSeed2011Seed · 2012-04-06 Raised $2.2M (real) Modeled valuation $97M (est)$2.2M$97MSeed2012+$2.2MCumulative $4.2M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.0M · 2011
Seed extension$2.2M · 2012

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$97.5M
Base estimate est.
$1.6M
Conservative case
$764.7M
Upside case
$11.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $88.8M · 2011-03-232011Seed · modeled $97.5M · 2012-04-062012
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
14.2 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
12 mo
Avg between rounds
$4.0M/yr
Capital velocity
15.3 yr
On record since
2011
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.6× of median
This company$4.2M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 1.3× above median
This company$2.2M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 1.5× above median
This company$97.5M
Sector median$64.2M

Raised more than 40% of sector peers (real $). Modeled value above 58% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #60 of 151.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Denali Medical II, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Signum Biosciences, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Health Elements, LLC · Seed Raised $4.0M · modeled $177.6M (est)Nkt Therapeutics Inc · Seed Raised $4.0M · modeled $177.6M (est)Surface Logix Inc · Seed Raised $4.0M · modeled $177.6M (est)Fe3 Medical, Inc. · Seed Raised $5.4M · modeled $177.1M (est)Proteonomix, Inc. · Seed Raised $3.8M · modeled $169.0M (est)SRS Medical Systems, Inc. · Seed Raised $3.8M · modeled $167.4M (est)Origen Therapeutics Inc /Ca · Seed Raised $3.7M · modeled $166.2M (est)Vivebio, LLC · Seed Raised $3.7M · modeled $163.1M (est)O2 Medtech Inc · Seed Raised $7.1M · modeled $160.3M (est)Biothera, Inc. · Seed Raised $3.5M · modeled $155.4M (est)Biotix Holdings Inc. (this company) Raised $4.2M · modeled $97.5M (est)Biotix Holdings Inc.
CompanyStageRaised · realValue · estvs peer med.
Denali Medical II, Inc.Seed$4.0M$177.6M2.05×
Signum Biosciences, Inc.Seed$4.0M$177.6M2.05×
Health Elements, LLCSeed$4.0M$177.6M2.05×
Nkt Therapeutics IncSeed$4.0M$177.6M2.05×
Surface Logix IncSeed$4.0M$177.6M2.05×
Fe3 Medical, Inc.Seed$5.4M$177.1M2.05×
Proteonomix, Inc.Seed$3.8M$169.0M1.95×
SRS Medical Systems, Inc.Seed$3.8M$167.4M1.93×
Origen Therapeutics Inc /CaSeed$3.7M$166.2M1.92×
Vivebio, LLCSeed$3.7M$163.1M1.88×
O2 Medtech IncSeed$7.1M$160.3M1.85×
Biothera, Inc.Seed$3.5M$155.4M1.79×
Biotix Holdings Inc. this companySeed$4.2M$97.5M1.13×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.0M2011-03-23$10.0M$88.8M90%
Seed$2.2M2012-04-06$11.0M$97.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.0M2011-03-23
    • First recorded raise — entered as Seed.
  2. Seed$2.2M2012-04-06
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
Intelligence
2013 ~Q2
Modeled next raise · ~12mo cadence
$2.4M
Modeled next size est.range $2.2M$3.9M
1.1×
Last step-up
$4.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Charles P. Cullen1 other2011-03
Paul J. Nowak1 other2011-03
Anthony J. Altig2011-03
David A. Freeman2011-03
Lawson P. DeVries2011-03
Ryan A. Kirkpatrick2011-03
Registry & provenance

Biotix Holdings Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1517218
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
IQuity Labs, Inc.BiotechnologySeed$4.3M$88.8Msame sector · same stage
ProFoldRX, Inc.BiotechnologySeed$4.3M$75.5Msame sector · same stage
Prosetta Bioconformatics IncBiotechnologySeed$4.0M$90.6Msame sector · same stage
Cellino Biotech IncBiotechnologySeed$4.0M$111.0Msame sector · same stage
Acylin Therapeutics, Inc.BiotechnologySeed$4.0M$88.8Msame sector · same stage
Cerberus Therapeutics, Inc.BiotechnologySeed$4.0M$78.5Msame sector · same stage
Sghuh LlcBiotechnologySeed$4.0M$81.0Msame sector · same stage
Torpedo Diagnostics, Inc.BiotechnologySeed$4.0M$88.8Msame sector · same stage
Frequently asked
How much funding has Biotix Holdings Inc. raised?
Biotix Holdings Inc. has raised approximately $4.2M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Biotix Holdings Inc.'s estimated valuation?
Provath's modeled valuation for Biotix Holdings Inc. is approximately $97.5M (modeled range $1.6M–$764.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Biotix Holdings Inc. at?
Biotix Holdings Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Fri Apr 06.
What does Biotix Holdings Inc. do and where is it based?
Biotix Holdings Inc. operates in the Biotechnology sector, based in SAN DIEGO.
Explore related

See where Biotix Holdings Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Biotix Holdings Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.